Susquehanna International Group, LLP Humanigen, Inc Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$0.12 - $0.23 $181 - $347	-1,513 Reduced 9.9%	13,768 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $1,722 - $3,828	-19,144 Reduced 55.61%	15,281 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $20,058 - $403,834	-133,720 Reduced 79.53%	34,425 $6,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $908,399 - $1.72 Million	-516,136 Reduced 75.43%	168,145 $298,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $462,096 - $1.01 Million	-255,302 Reduced 27.17%	684,281 $2.06 Million
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1.84 Million - $4.12 Million	501,378 Added 114.42%	939,583 $3.5 Million
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $210,426 - $632,697	35,485 Added 8.81%	438,205 $2.6 Million
Q2 2021 Aug 11, 2021	BUY	$13.54 - $22.74 $882,726 - $1.48 Million	65,194 Added 19.32%	402,720 $7 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $2.69 Million - $4.97 Million	208,601 Added 161.8%	337,526 $6.45 Million
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $1.03 Million - $2.79 Million	128,925 New	128,925 $2.26 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.